

## Coding and Noncoding Variation of the Human Calcium-Channel $\beta_4$ -Subunit Gene *CACNB4* in Patients with Idiopathic Generalized Epilepsy and Episodic Ataxia

Andrew Escayg,<sup>1</sup> Michel De Waard,<sup>2</sup> David D. Lee,<sup>1</sup> Delphine Bichet,<sup>2</sup> Peter Wolf,<sup>3</sup> Thomas Mayer,<sup>3</sup> Janine Johnston,<sup>4</sup> Robert Baloh,<sup>5</sup> Thomas Sander,<sup>6</sup> and Miriam H. Meisler<sup>1</sup>

<sup>1</sup>Department of Human Genetics, University of Michigan, Ann Arbor; <sup>2</sup>INSERM U464, Institut Federatif Jean Roche, Faculté de Médecine Nord, Marseille; <sup>3</sup>Clinic Mara, Epilepsy Center Bethel, Bielefeld, Germany; <sup>4</sup>Department of Neurology, University of Manitoba, Winnipeg; <sup>5</sup>Department of Neurology, University of California School of Medicine, Reed Neurological Research Center, Los Angeles; and <sup>6</sup>Department of Neurology, University Hospital Charité, Campus Virchow Clinic, Humboldt University of Berlin, Berlin

Inactivation of the  $\beta_4$  subunit of the calcium channel in the mouse neurological mutant *lethargic* results in a complex neurological disorder that includes absence epilepsy and ataxia. To determine the role of the calcium-channel  $\beta_4$ -subunit gene *CACNB4* on chromosome 2q22–23 in related human disorders, we screened for mutations in small pedigrees with familial epilepsy and ataxia. The premature-termination mutation R482X was identified in a patient with juvenile myoclonic epilepsy. The R482X protein lacks the 38 C-terminal amino acids containing part of an interaction domain for the  $\alpha_1$  subunit. The missense mutation C104F was identified both in a German family with generalized epilepsy and praxis-induced seizures and in a French Canadian family with episodic ataxia. These coding mutations were not detected in 255 unaffected control individuals (510 chromosomes), and they may be considered candidate disease mutations. The results of functional tests of the truncated protein R482X in *Xenopus laevis* oocytes demonstrated a small decrease in the fast time constant for inactivation of the cotransfected  $\alpha_1$  subunit. Further studies will be required to evaluate the *in vivo* consequences of these mutations. We also describe eight noncoding single-nucleotide substitutions, two of which are present at polymorphic frequency, and a previously unrecognized first intron of *CACNB4* that interrupts exon 1 at codon 21.

### Introduction

Inherited movement and seizure disorders are a major clinical burden, the molecular etiology of which remains, for the most part, undefined. The results of recent studies have indicated that mutations in the neuronal voltage-gated ion channels are a major contributor to these conditions (Cooper and Jan 1999; McNamara 1999). Mutations in five neuronal ion-channel genes have been associated with idiopathic epilepsies. These mutations are found in the  $\alpha$  and  $\beta_1$  subunits of the voltage-gated sodium channel in generalized epilepsy with febrile seizures plus (GEFS+) (Wallace et al. 1998; Escayg et al. 2000), in the potassium-channel genes *KCNQ2* and *KCNQ3* in benign familial neonatal convulsions (Biervert et al. 1998; Charlier et al. 1998; Singh et al. 1998), and in the  $\alpha_4$  subunit of the neuronal nicotinic acetylcholine

receptor in autosomal dominant nocturnal frontal-lobe epilepsy (Steinlein et al. 1995). The voltage-gated sodium-channel gene *SCN5A* has also been implicated in the seizure activity of individuals with LQT3 (Hartmann et al. 1999). With regard to ion channels and ataxia, the potassium-channel gene *KCNA1* and the calcium-channel gene *CACNA1A* are associated with episodic ataxia type 1 and type 2, respectively. Other alleles of *CACNA1A* cause spinocerebellar ataxia type 6 and familial hemiplegic migraine, demonstrating that different mutations in the same ion-channel gene can produce different neurological phenotypes. In the mouse, allelic mutations in the sodium-channel gene *SCN8A* result in ataxia, dystonia, and paralysis (Meisler et al. 1997; Sprunger et al. 1999), and several other mouse neurological mutants have been associated with ion channels (Burgess and Noebels 1999).

The voltage-gated calcium channels play a critical role in neurotransmitter release in neurons. Calcium channels are multimeric proteins that contain an  $\alpha_1$  subunit with pore-forming domains and the auxiliary subunits  $\beta$ ,  $\gamma$ , and  $\alpha_2\delta$  (Perez-Reyes and Schneider 1994). At least seven distinct mammalian genes encoding calcium-channel  $\alpha_1$  subunits have been identified. Four paralogous genes encoding the  $\beta$  subunits  $\beta_1$ – $\beta_4$  have been

Received December 22, 1999; accepted for publication February 7, 2000; electronically published April 4, 2000.

Address for correspondence and reprints: Dr. Miriam H. Meisler, Department of Human Genetics, University of Michigan, 4708 Medical Science II, Ann Arbor, MI 48109-0618. E-mail: meislerm@umich.edu

© 2000 by The American Society of Human Genetics. All rights reserved. 0002-9297/2000/6605-0008\$02.00

mapped to conserved chromosome segments in human and mouse (Plummer and Meisler 1999). Interaction of  $\alpha_1$  and  $\beta$  subunits contributes to the diversity of calcium currents by modulation of current amplitude, voltage dependence, and kinetics of activation and inactivation (De Waard and Campbell 1995). The  $\beta$  subunits also appear to participate in the membrane trafficking of the  $\alpha_1$  subunit (Yamaguchi et al. 1998; Gerster et al. 1999). The amino acid sequences of the four mammalian  $\beta$  subunits differ by ~20%. All  $\beta$  subunits are expressed in the brain, with regional differences in the levels of expression. The  $\beta_4$  subunit is the most highly expressed subunit in the cerebellum (Burgess et al. 1999).

We demonstrated that a null mutation in the  $\beta_4$  subunit is responsible for an autosomal recessive neurological disorder in the mouse mutant *lethargic* (Burgess et al. 1997). A 4-bp insertion into a splice-donor site results in exon skipping and premature termination of the protein upstream of the major site for interaction with the  $\alpha_1$  subunit. Absence of  $\beta_4$ -subunit protein in *lethargic* brain has been confirmed with the use of specific antisera (McEnery et al. 1998). The lack of  $\beta_4$  subunits results in severe ataxia, focal motor abnormalities, and brief periods of behavioral immobility that are accompanied by bilaterally synchronous, generalized cortical spike-wave discharges with a mean duration of 1.5 s and a frequency of 100/h (Hosford et al. 1992). These spontaneous absence seizures share behavioral, electrographic, and pharmacological responses with absence seizures in patients (Hosford et al. 1999). The  $\beta_4$ -subunit deficiency results in a selective decrease in excitatory synaptic transmission in somatosensory thalamic neurons (Caddick et al. 1999). Despite the compensatory association of  $\alpha_1$ -subunit proteins with other  $\beta$  subunits (Burgess et al. 1999), only 20% of *lethargic* homozygotes survive beyond weaning.

To determine the effects of mutations in the human orthologue of *lethargic*, we characterized the exon structure of the human calcium-channel  $\beta_4$ -subunit gene (*CACNB4* [MIM 601949]) and mapped the gene to chromosome 2q22-23 (Escayg et al. 1998). Genes for two epilepsy syndromes—generalized epilepsy with febrile seizures plus (GEFS+) and febrile seizures (FEB3)—have recently been mapped to this chromosome region (Baulac et al. 1999; Moulard et al. 1999; Peiffer et al. 1999; Lopez-Cendes et al. 2000). In each family, one or two recombinants placed the disease gene distal to markers D2S141 and D2S284. Since we mapped *CACNB4* proximal to these markers on the GB4 radiation-hybrid panel, it is apparently excluded as a candidate gene (Escayg et al. 1998). We now report the results of screening for *CACNB4* mutations in affected individuals from small pedigrees with common subtypes of idiopathic

generalized epilepsy and hereditary episodic ataxia. The results of exon amplification and conformation-sensitive gel electrophoresis (CSGE) revealed several noncoding polymorphic variants and two coding mutations in affected individuals.

## Material and Methods

### Mutation Detection

The 14 exons of *CACNB4* were individually amplified from genomic DNA, by use of primers designed from intron sequences. PCR amplification was performed for 32 cycles of 1 min at 94°C, 45 s at 60°C, and 1 min at 72°C. PCR products were incubated for 10 min at 99°C, followed by 30 min at 68°C to facilitate heteroduplex formation, and they were analyzed by CSGE, as described elsewhere (Raman et al. 1997). Exons with electrophoretic variants were reamplified, PCR products were purified from agarose gels by use of the Qiaex II gel extraction kit (Qiagen), and manual sequencing was performed with use of the Thermo Sequenase sequencing kit (USB).

### Patients

DNA was obtained from index patients from 90 families with idiopathic generalized epilepsy (Sander et al. 1999) and from 71 families with episodic ataxia. The families with epilepsy included 19 families with childhood absence epilepsy, 22 with juvenile absence epilepsy, and 49 with juvenile myoclonic epilepsy (JME). More than 250 unrelated controls were tested for variants detected in the affected individuals. The clinical features of pedigrees with coding variants of *CACNB4* are described in the Appendix. Informed consent was obtained from all participants.

### Functional Tests in *Xenopus laevis* Oocytes

The mutations R482X and C104F were introduced into the previously described rat  $\beta_4$ -subunit cDNA (Walker et al. 1998). The rat and human *CACNB4* proteins exhibit 99% sequence identity (512/519 amino acids; Escayg et al. 1998), and human residue C104 corresponds to rat C103. R482X was constructed by means of PCR amplification of the corresponding region of the wild-type cDNA with the addition of a Kozak sequence and a termination codon. The PCR product was subcloned into pcDNA3, with the use of *HindIII* and *BamHI* sites added to the PCR primers. The C104F mutation was introduced by use of the QuickChange site-directed mutagenesis kit (Stratagene) with the following mutagenic primers: 5'-AAA ACG AAT GTG AGC TAC TTT GGT GCC CTG GAT GAG GAT GTG-3' (forward) and 5'-CAC ATC CTC ATC CAG GGC ACC AAA GTA GCT CAC ATT CGT TTT CAC-3' (reverse). Oocytes

were injected with each  $\beta_4$ -subunit mRNA (0.1  $\mu\text{g}/\mu\text{l}$ ), in combination with the  $\alpha_1$ -subunit gene *CACNA1A* (0.4  $\mu\text{g}/\mu\text{l}$ ). Electrophysiological recordings were performed 4–5 d after injection, as described elsewhere (Walker et al.1998).

**Results**

*An Additional Intron in CACNB4*


We have previously reported that the *CACNB4* coding sequence is interrupted by 12 introns at positions corresponding to the introns of the human *CACNB3* gene (Escayg et al. 1998). Amplification of genomic DNA, by use of primers from the 5' untranslated region and intron 1, generated a product that was 0.5 kb longer than that which was predicted by the cDNA. Sequence analysis identified a small intron (535 bp) that interrupts exon 1 (GenBank accession number AF216867). The first two exons of *CACNB4* are now designated as “1A” and “1B” (fig. 1A).

*Noncoding Variation in CACNB4*

Eight noncoding variants were identified by CSGE analysis of exons amplified from genomic DNA (table 1). Two of these noncoding variants are present at polymorphic frequencies  $\geq 1\%$ , whereas the others are rare variants.

*Premature-Termination Mutation in a Family with JME*

The proband in pedigree A (individual I-1; fig. 2A) exhibited JME. Her symptoms include characteristic bilateral myoclonic jerks of the shoulders and arms without loss of consciousness, sporadic absence seizures, and generalized tonic-clonic seizures (GTCS). A unique conformer of exon 13 was observed in in-



**Figure 1** Structure and interactions of *CACNB4*. A, Intron/exon junctions for exons 1A and 1B. The indicated 5' end of exon 1A corresponds to the translation-initiation site. The intron sequence is from GenBank (accession number AF216867). B, Locations of mutations in *CACNB4*. Two domains of *CACNB4* that interact with the  $\alpha_1$  subunit of the voltage-gated calcium channel are indicated. In the mouse *lethargic* mutant (designated as “*lh*”), the protein is truncated upstream of the major binding site. In human mutation R482X, the protein is truncated in the middle of a domain that interacts with the C-terminus of the  $\alpha_{1A}$  subunit.

dividual I-1, by means of CSGE (fig. 2B, lane 1). Sequencing demonstrated heterozygosity for a C→T transition (fig. 2C). This mutation generates a premature stop codon (R482X) and eliminates 38 amino acids comprising the C-terminal 10% of the protein. This mutation can also be detected by generation of a novel *AluI* site (fig. 2D).


**Table 1**

**Single-Nucleotide Variants in Human *CACNB4***

SUBSTITUTION TYPE AND LOCATION	NUCLEOTIDE <sup>a</sup>	MAJOR/MINOR ALLELE	FREQUENCY OF MINOR ALLELE <sup>b</sup>	PRIMER	
				Forward	Reverse
<b>Noncoding:</b>					
Exon 9	762	T/A	<.01	9F: CTG GCT TGT TCT GTT CTG TG	9R: GCA CAG CTT GAA GAA GTA CC
Exon 12	1239	G/A	.03	12F: AAC TGC CCA TAT AGC ACC TC	12R: TCC ATC CTA ATC AAG AAG TTC CC
Exon 13	1413	G/A	<.01	13F: GCA TCT TAT TGT ACA GAT CC	13R: GCT ATC TTA GCC AAG TTA AG
Exon 13	1567	T/C	<.01	13F: GCA TCT TAT TGT ACA GAT CC	13R: GCT ATC TTA GCC AAG TTA AG
Intron 2	268 – 37	C/T	.01	3F: CAT TTG AGA TCC CTC TTT GG	3R: GTT TGG CTC AGA GCT GAT TC
Intron 3	390 + 22	T/C	<.01	3F: CAT TTG AGA TCC CTC TTT GG	3R: GTT TGG CTC AGA GCT GAT TC
Intron 5	599 – 15	G/A	<.01	6F: AGG GAC AAA TGG GTA CAT TC	7R: GGG TGC TCG ATC AAG AAC TG
Intron 6	619 – 24	C/T	<.01	6F: AGG GAC AAA TGG GTA CAT TC	7R: GGG TGC TCG ATC AAG AAC TG
<b>Coding:</b>					
Exon 3 (C104F)	311	G/T	<.006	3F: CAT TTG AGA TCC CTC TTT GG	3R: GTT TGG CTC AGA GCT GAT TC
Exon 13 (R482X)	1444	C/T	<.006	13F: GCA TCT TAT TGT ACA GAT CC	13R: GCT ATC TTA GCC AAG TTA AG

<sup>a</sup> Nucleotide positions are based on the cDNA sequence (GenBank accession number AF038852; Escayg et al. 1998).

<sup>b</sup> Frequencies are based on the results of analysis of 500–1,000 chromosomes.



**Figure 2** R482X mutation in a family with JME. *A*, Affected individuals (*blacked symbols*) are shown, with the arrow pointing to the proband. *B*, Results of CSGE of exon 13. A unique band seen in the proband (lane 1, *arrow*) is not observed in three unrelated controls (lanes 2–4). *C*, The sequence of exon 13 demonstrates that the proband is heterozygous for a C→T transition that generates the premature-termination codon R482X. *D*, Results of a restriction-site assay for R482X. A 388-bp fragment obtained by digestion of wild-type exon 13 with *AluI* is shown (lanes 2–4). The internal *AluI* site produced by R482X results in two fragments (209 bp and 179 bp; see lane 1).

Individual II-3 is considered to be affected, on the basis of an abnormal electroencephalogram (EEG) with generalized 3/s spike-wave discharges (for clinical details, see the Appendix). To date, efforts to obtain DNA samples from individuals I-2 and II-1 have not been successful.

#### Segregation of C104F in Two Pedigrees with Different Neurological Phenotypes

The proband in pedigree B (individual I-1; fig. 3A) and his son (individual II-3) exhibit idiopathic generalized epilepsy with rare GTCS, atypical absence seizures, and evidence of an unusual cognitive trigger of seizure initiation. An exon 3 variant was detected, by means of CSGE, in both affected individuals (fig. 3C, *left*). The results of sequence analysis demonstrated heterozygosity for a G→T transversion (fig. 3D) resulting in the replacement of cysteine residue 104 by phenylalanine (C104F). The unaffected members of family B do not carry the mutation.

C104F was also observed in an unrelated French Canadian family with episodic ataxia (pedigree C; fig. 3B and C). In this family, five affected and two asymptomatic


individuals carry the C104F mutation, consistent with incomplete penetrance (70%) if this is a causal mutation.

#### Analysis of R482X and C104F in Control Samples

We analyzed exon 3 and exon 13 in 255 control samples (510 chromosomes), including 133 asymptomatic individuals of northern European origin (Sander et al. 1999) and 80 CEPH parents. R482X and C104F were not present in the controls, indicating that the allele frequencies for both mutations are <.006 (95% confidence level).

#### Functional Analysis of R482X and C104F in *Xenopus* Oocytes

To evaluate their effects on channel properties, the mutations R482X and C104F were introduced into the rat  $\beta_4$ -subunit cDNA and were coexpressed with the  $\alpha_{1A}$ -subunit in *Xenopus* oocytes. Expression of the wild-type  $\beta_4$  subunit together with the  $\alpha_{1A}$  subunit produces a slowly inactivating inward  $Ba^{2+}$  current (fig. 4a). This current is not seen in the absence of the  $\beta_4$  subunit. Both




**Figure 3** C104F mutation cosegregating with neurological disease in two unrelated pedigrees. *A*, Pedigree B, which is of German origin and exhibits idiopathic generalized epilepsy. *B*, Pedigree C, which is of French Canadian origin and exhibits episodic ataxia. *C*, CSGE analysis of exon 3 from pedigree B (left) and from pedigree C (right). The variant conformer is indicated (arrow). Numbers above the lanes correspond to individuals in the pedigrees. *D*, Sequence of exon 3 that demonstrates a G→T transversion that changes the wild-type cysteine 104 codon to phenylalanine. *CACNB4* genotypes are indicated below the symbols. G = allele 1; T = allele 2.

mutants were able to associate with the  $\alpha_{1A}$  subunit, to produce inward currents (fig. 4a). Increases in current density of 1.4-fold and 1.3-fold were observed for R482X and C104F, respectively (fig. 4b). There was no change in the voltage dependence of activation.

An interesting change in the kinetics of inactivation

was observed for the truncated R482X mutant. The wild-type  $\beta_4$  subunit produces biphasic inactivation (Walker et al. 1998) with a fast-inactivating component (F), a slower inactivating component (S), and a non-inactivating component (NI). For test potentials of 0–20 mV, the F component for the R482X mutant is accel-



**Figure 4** Electrophysiological analysis of mutant  $\beta_4$  subunits. *Xenopus* oocytes were injected with mRNA from either the wild-type or mutant  $\beta_4$  subunit, in combination with the *CACNA1A*  $\alpha_1$  subunit. **A**, Sets of current traces at test potentials of  $-20$ ,  $-10$ ,  $0$ ,  $10$ ,  $20$ , and  $30$  mV. The potential of half-activation was not significantly modified by the mutations, with  $V_{1/2} = -12.2 \pm 0.9$  mV ( $\beta_4$ -subunit R482X,  $n = 8$ ),  $-11.3 \pm 0.6$  mV ( $\beta_4$ -subunit C104F;  $n = 8$ ), and  $-10 \pm 0.1$  mV (wild-type  $\beta_4$  subunit;  $n = 8$ ). There was a small shift in the voltage dependence of inactivation of the  $\alpha_{1A}$   $\beta_4$ -subunit R482X, with half-inactivation potentials of  $V_{1/2} = -41.1 \pm 0.4$  mV ( $\beta_4$ -subunit R482X;  $n = 7$ ) and  $V_{1/2} = -37.4 \pm 0.5$  mV (wild-type  $\beta_4$  subunit;  $n = 6$ ). **B**, Average current density generated by wild-type and mutant channels at a membrane depolarization of  $0$  mV (peak current amplitude for each subunit combination). The average current density of the  $\alpha_{1A}$  wild-type  $\beta_4$  subunit ( $1.90 \pm 0.15 \mu\text{A}/\mu\text{F}$ ;  $n = 8$ ) at  $0$  mV was increased 1.4- and 1.3-fold, to  $2.72 \pm 0.25$  ( $n = 8$ ) and  $2.45 \pm 0.24$  ( $n = 8$ ), with  $\beta_4$ -subunit R482X and  $\beta_4$ -subunit C104F, respectively. Asterisks (\*) denote statistical significance ( $t$  test;  $P \leq .1$ ). **C**, Average time constants for the fast component of inactivation. At a membrane depolarization of  $10$  mV, the wild-type current inactivates along three components, a fast-inactivating component (F) with an average time constant of  $89.6 \pm 5.3$  ms ( $n = 7$ ), which constitutes  $19.9 \pm 3.4\%$  of the total current, a slower inactivating component (S) with an average time constant of  $323 \pm 37.4$  ms ( $73.9 \pm 3.1\%$ ), and a noninactivating (NI) component ( $6.2 \pm 0.9\%$ ). With  $\beta_4$ -subunit R482X, there was no change in the proportion of each component, but the F component demonstrated a faster rate of decrease ( $50.7 \pm 4.7$  ms;  $n = 6$ ). The time constants for  $\beta_4$ -subunit R482X at  $0$  and  $10$  mV are statistically significantly different from those for wild type ( $P < .01$ ). Values are mean  $\pm$  SEM.

erated. For example, at  $10$  mV, the time constant for R482X is  $50.7 \pm 4.7$  ms, compared with  $89.6 \pm 5.3$  ms for the wild-type  $\beta_4$  subunit (fig. 4c). This change is similar to that previously observed for constructs with deletions of the C-terminus (Walker et al. 1998). No kinetic alteration was observed for the C104F mutation (fig. 4c and data not shown).

## Discussion

The  $\beta_4$  calcium-channel subunit is a highly conserved protein, with 99% sequence identity between human and rat (Escayg et al. 1998). We observed a very low level of polymorphism in this initial study of human variation. In addition to several noncoding polymor-

phisms in *CACNB4*, we identified two coding changes that are potential disease mutations. The positions of these mutations and the mouse *lethargic* mutation are shown in figure 1B.

The N- and C-terminal portions of the  $\alpha_1$  and  $\beta$  subunits contain several functional domains that modulate channel kinetics (Wei et al. 1994; de Leon et al. 1995; Tareilus et al. 1997; Cens et al. 1999; Walker et al. 1999). The C-terminus of the  $\beta_4$  subunit interacts directly with the C-terminus of the  $\alpha_{1A}$  subunit (Walker et al. 1998). Experimental deletion of 109 amino acids from the C-terminus of the  $\beta_4$  subunit eliminated binding to the C-terminus of the  $\alpha_{1A}$  subunit and decreased the time constant for the fast component of inactivation (Walker et al. 1998). The R482X truncation mutant

lacking the 38 C-terminal amino acids had a similar effect on the time constant, indicating that these residues are involved in the interaction with the C-terminus of the  $\alpha_{1A}$  subunit. The decrease in time constant observed with R482X would have the effect of increasing the rate of channel inactivation and reducing the net inward flow of calcium ions into activated neurons. This type of effect may be quite pronounced during short and rapid alterations in membrane potentials, such as those that occur during action potentials, and could be of clinical significance. The deletion of two consensus phosphorylation sites in the R482X channel could also have an effect on its activity (Hell et al. 1996; Chien et al. 1998).

Although the C104F mutation did not alter channel kinetics, other aspects of  $\beta_4$ -subunit function may be affected by this mutation. Replacement of cysteine with a large hydrophobic phenylalanine residue in the C104F mutation could disrupt the conformation of this domain, which is evolutionarily conserved and is thought to be involved in interaction with other proteins (Walker and De Waard 1998; Hanlon et al. 1999). Such interactions could be crucial to channel clustering or targeting without affecting the channel gating. The increase in current amplitude observed for the mutant channels could also contribute to abnormal firing properties.

The clinical features of individuals in pedigree C closely resemble those of patients with mutations in the calcium-channel  $\alpha_{1A}$  subunit resulting in episodic ataxia type 2 (EA2). The similarities include duration of attacks, interictal imbalance and nystagmus, response to acetazolamide, and apparently incomplete penetrance. The only obvious difference is the earlier onset in infancy in patients with EA2. The proband in family 3 was screened for mutations in the  $\alpha_{1A}$  subunit by means of SSCP, but no mutations were detected. The similarities to EA2 are consistent with a causal role for the C104F mutation in pedigree C.

The observation that the C104F mutation is associated with episodic ataxia in one family and with epilepsy in another family suggests either that it is a neutral polymorphism or that genetic and environmental factors modify the clinical effects of the mutation. The null mutation of *Cacnb4* in the *lethargic* mouse results in seizures and ataxia, indicating that *CACNB4* can contribute to both phenotypes. Another mutation conferring both episodic ataxia and susceptibility to seizures was described in a human potassium channel (Zuberi et al. 1999). We have recently mapped a genetic modifier locus that dramatically alters the phenotype associated with a sodium-channel mutation in mouse (Sprunger et al. 1999). It would not be surprising if background genetic variation in the human population could influence the phenotypic consequences of ion-channel mutations such as C104F.

Are the R482X and C104F mutations responsible for the neurological disease in these pedigrees? The mutations cosegregate with the disease in affected individuals, are associated with phenotypes similar to those in the mouse mutant, and are not present in 255 controls; however, the functional alterations in the oocyte expression system are subtle, and the pedigrees are too small to provide strong evidence for linkage. Identification of additional patients with mutations in *CACNB4* and demonstration of functional consequences in a mammalian assay system could provide additional support for a causal role for these mutations. Because ataxia and epilepsy can result from mutations in several different ion-channel genes, continued identification of disease-causing mutations will be a necessary step toward the goal of developing therapies that are tailored to each specific genetic disorder.

## Acknowledgments

---

We are grateful to the families, for their participation in this study. We thank Sandrine Geib, for assistance with oocyte isolation and injection. This work was supported in part by National Institutes of Health grants NS34709 (to M.H.M.) and PO1 DC02952 (to R.B.), grant Sa434/2-2 from the German Research Community (to T.S.), and the INSERM Institute (to M.D.W.).

## Appendix

---

### Clinical Features of Three Pedigrees with Coding Variants of *CACNB4*

Beginning at age 9 years, the proband in pedigree A experienced sporadic typical absences (brief spells of loss of consciousness) and repetitive bilateral myoclonic jerks in the shoulders and arms after awakening, without loss of consciousness. She later experienced several GTCS, usually within 1 h of awakening. Her epilepsy syndrome was classified as JME (Commission on Classification and Terminology of the International League Against Epilepsy 1989). EEGs of the proband's daughter showed generalized 3/s spike-wave discharges without epileptic seizures.

The affected father and son in pedigree B presented with an atypical but similar clinical syndrome of idiopathic generalized epilepsy with rare juvenile atypical prolonged absences and occasional GTCS. The proband (individual I-1; fig. 3A) had normal intellectual and psychomotor development. One febrile convulsion occurred at age 3 years. After age 6 years, he had occasional GTCS, predominantly on awakening, and, after age 12 years, occasional episodes of absence were described. The interictal EEGs showed atypical generalized spike-

wave discharges in the resting EEG. The ictal EEG was highly unusual, with initial generalized desynchronization and flattening, followed by irregular generalized high-voltage delta activity interspersed with spikes and wave. The syndrome was classified as idiopathic generalized epilepsy with GTCS on awakening, probable absence seizures, and praxis-induced seizures. A prolonged atypical absence occurred in the the eldest son (individual II-3) at age 14 years, while he was playing cards. At age 17 years, he experienced GTCS shortly after awakening. Two years later, he experienced a generalized tonic seizure while playing a complex strategic game after sleep withdrawal. He experiences occasional prolonged staring spells when lacking sleep. His interictal EEG presents some fast generalized spike-wave activity (4–5 Hz) that increases with hyperventilation. Intellectual and psychomotor development was normal. Both affected individuals report that seizures are precipitated by playing complex strategic games (praxis induction), suggesting an unusual cognitive trigger of seizure initiation (Inoue et al. 1992; Ritaccio 1994). Clinical exploration revealed no evidence for epileptic seizures in either the 51-year-old mother (individual II-2) or the 17-year-old son (individual II-4). Individual II-4 had normal EEG results.

After age 20 years, the proband in pedigree C (individual III-13; fig. 3B) experienced recurrent episodes of vertigo and ataxia that lasted for several hours. Interictal examination revealed spontaneous downbeat and gaze-evoked nystagmus and mild dysarthria and truncal ataxia. The proband's mother had identical episodes of vertigo and ataxia after age 30 years as well as long-standing dysarthria and imbalance. Acetazolamide prevented the attacks in both the proband and mother, and the attacks recurred when acetazolamide was briefly discontinued. A maternal aunt (individual II-10) has reported mild episodes of ataxia for the past 5 years. Seven years ago, another maternal aunt (individual II-9) experienced one prolonged episode of vertigo and imbalance that lasted for several weeks. Although the proband's 12-year-old son (individual IV-16) had febrile seizures as a child and exhibits dysarthria and imbalance, he has not had episodes of vertigo or ataxia. The other family members are asymptomatic, including individuals II-3 and IV-17, both of whom carry the C104F mutation.

### Electronic-Database Information

Accession numbers and URLs for data in this article are as follows:

CEPH, <http://www.cephb.fr/>  
GenBank, <http://www.ncbi.nlm.nih.gov/Genbank/index.html>  
(for the small intron of 535 bp that interrupts exon 1 [accession number AF216867])

Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/> (for *CACNB4* [MIM 601949])

### References

- Baulac S, Gourfinkel-An I, Picard F, Rosenberg-Bourgin M, Prud'homme J-F, Baulac M, Brice A, et al (1999) A second locus for familial generalized epilepsy with febrile seizures plus maps to chromosome 2q21-q33. *Am J Hum Genet* 65: 1078–1085
- Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, Steinlein OK (1998) A potassium channel mutation in neonatal human epilepsy. *Science* 279:403–406
- Burgess DL, Biddlecome GH, McDonough SI, Diaz ME, Zilinski CA, Bean BP, Campbell KP, et al (1999)  $\beta$  subunit reshuffling modifies N- and P/Q-type  $\text{Ca}^{2+}$  channel subunit compositions in lethargic mouse brain. *Mol Cell Neurosci* 13:293–311
- Burgess DL, Jones JM, Meisler MH, Noebels JL (1997) Mutation of the  $\text{Ca}^{2+}$  channel  $\beta$  subunit gene *Cchb4* is associated with ataxia and seizures in the lethargic (*lh*) mouse. *Cell* 88:385–392
- Burgess DL, Noebels JL (1999) Voltage-dependent calcium channel mutations in neurological disease. *Ann NY Acad Sci* 868:199–212
- Caddick SJ, Wang C, Fletcher CF, Jenkins NA, Copeland NG, Hosford DA (1999) Excitatory but not inhibitory synaptic transmission is reduced in lethargic (*Cacnb4lh*) and tottering (*Cacna1atg*) mouse thalami. *J Neurophysiol* 81:2066–2074
- Cens T, Restituito S, Charnet P (1999) Regulation of  $\text{Ca}^{2+}$ -sensitive inactivation of a 1-type  $\text{Ca}^{2+}$  channel by specific domains of  $\beta$  subunits. *FEBS Lett* 450:17–22
- Charlier C, Singh NA, Ryan SG, Lewis TB, Reus BE, Leach RJ, Leppert M (1998) A pore mutation in a novel KQT-like potassium channel in an idiopathic epilepsy family. *Nat Genet* 18:53–55
- Chien AJ, Hosey MM (1998) Post-translational modifications of  $\beta$  subunits of voltage-dependent calcium channels. *J Bioenerg Biomembr* 30:377–386
- Commission on Classification and Terminology of the International League Against Epilepsy (1989) Proposal for revised classification of epilepsies and epileptic syndromes. *Epilepsia* 30:389–399
- Cooper EC, Jan LY (1999) Ion channel genes and human neurological disease: recent progress, prospects, and challenges. *Proc Natl Acad Sci USA* 96:4759–4766
- de Leon M, Wang Y, Jones L, Perez-Reyes E, Wei X, Soong TW, Snutch TP, et al (1995) Essential  $\text{Ca}^{2+}$ -binding motif for  $\text{Ca}^{2+}$ -sensitive inactivation of L-type  $\text{Ca}^{2+}$  channels. *Science* 270:1502–1506
- De Waard M, Campbell KP (1995) Subunit regulation of the neuronal  $\alpha_{1A}$   $\text{Ca}^{2+}$  channel expressed in *Xenopus* oocytes. *J Physiol* 485:619–634
- Escayg A, Jones JM, Kearney JA, Hitchcock PF, Meisler MH (1998) Calcium channel  $\beta 4$  (*CACNB4*): human ortholog of the mouse epilepsy gene *lethargic*. *Genomics* 50:14–22
- Escayg A, MacDonald BT, Meisler MH, Baulac S, Huberfeld G, An-Gourfinkel I, Brice A, LeGuern E, et al (2000) Mutations of *SCN1A*, encoding a neuronal sodium channel, in two families with GEFS+2. *Nat Genet* 24:343–345



- Gerster U, Neuhuber B, Groschner K, Striessnig J, Flucher BE (1999) Current modulation and membrane targeting of the calcium channel  $\alpha 1c$  subunit are independent functions of the  $\beta$  subunit. *J Physiol* 517:353–368
- Hanlon MR, Berrow NS, Dolphin AC, Wallace BA (1999) Modelling of a voltage-dependent  $\text{Ca}^{2+}$  channel  $\beta$  subunit as a basis for understanding its functional properties. *FEBS Lett* 445:366–370
- Hartmann HA, Colom LV, Sutherland ML, Noebels JL (1999) Selective localization of cardiac *SCN5A* sodium channels in limbic regions of rat brain. *Nat Neurosci* 2:593–595
- Hell JW, Westenbroek RE, Breeze LJ, Wang KK, Chavkin C, Catterall WA (1996) N-methyl-D-aspartate receptor-induced proteolytic conversion of postsynaptic class C L-type calcium channels in hippocampal neurons. *Proc Natl Acad Sci USA* 93:3362–3367
- Hosford DA, Clark S, Cao Z, Wilson WA, Lin F-H, Morrisett RA, Huin A (1992) The role of GABAB receptor activation in absence seizures of lethargic (*lh/lh*) mice. *Science* 257:398–401
- Hosford DA, Lin FH, Wang Y, Caddick SJ, Rees M, Parkinson NJ, Barclay J, et al (1999) Studies of the lethargic (*lh/lh*) mouse model of absence seizures: regulatory mechanisms and identification of the *lh* gene. *Adv Neurol* 79:239–252
- Inoue Y, Suzuki S, Watanabe Y, Yagi K, Seino M (1992) Non-lesional reflex epilepsy evoked by non-verbal higher cerebral activities. *J Jpn Epilepsy Soc* 10:1–9
- Lopes-Cendes I, Scheffer IE, Berkovic SF, Rousseau M, Andermann E, Rouleau GA (2000) A new locus for generalized epilepsy with febrile seizures plus maps to chromosome 2. *Am J Hum Genet* 66:698–701
- McEnery MW, Copeland TD, Vance CL (1998) Altered expression and assembly of N-type calcium channel  $\alpha_{1B}$  and  $\beta$  subunits in epileptic lethargic (*lh/lh*) mouse. *J Biol Chem* 273:21435–21438
- McNamara JO (1999) Emerging insights into the genesis of epilepsy. *Nature* 399 (Suppl 6738):A15–22
- Meisler MH, Sprunger LK, Plummer NW, Escayg A, Jones JM (1997) Ion channel mutations in mouse models of inherited neurological disease. *Ann Med* 29:569–574
- Moulard B, Guipponi M, Chaigne D, Mouthon D, Buresi C, Malafosse A (1999) Identification of a new locus for generalized epilepsy with febrile seizures plus (GEF+) on chromosome 2q24-q33. *Am J Hum Genet* 65:1396–1400
- Peiffer A, Thompson J, Charlier C, Otterud B, Varvil T, Pappas C, Barnitz C, et al (1999) A locus for febrile seizures (FEB3) maps to chromosome 2q23-24. *Ann Neurol* 46:671–678
- Perez-Reyes E, Schneider T (1994) Calcium channels: structure, function, and classification. *Drug Dev Res* 33:295–318
- Plummer NW, Meisler MH (1999) Evolution and diversity of mammalian sodium channel genes. *Genomics* 57:323–331
- Raman IM, Sprunger LK, Meisler MH, Bean BP (1997) Altered subthreshold sodium currents and disrupted firing patterns in Purkinje neurons of *Scn8a* mutant mice. *Neuron* 19:881–891
- Ritaccio AL (1994) Reflex seizures. *Neurol Clin* 12:57–83
- Sander T, Peters C, Kammer G, Samochowiec J, Zirra M, Mischke D, Ziegler A, et al (1999) Association analysis of exonic variants of the gene encoding the  $\text{GABA}_B$  receptor and idiopathic generalized epilepsy. *Am J Med Genet* 88:305–310
- Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, et al (1998) A novel potassium channel gene, *KCNQ2*, is mutated in an inherited epilepsy of newborns. *Nat Genet* 18:25–29
- Sprunger LK, Escayg A, Tallaksen-Greene S, Albin RL, Meisler MH (1999) Dystonia associated with mutation of the neuronal sodium channel *Scn8a* and identification of the modifier locus *Scnm1* on mouse chromosome 3. *Hum Mol Genet* 8:471–479
- Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, Scheffer IE, et al (1995) A missense mutation in the neuronal nicotinic acetylcholine receptor  $\alpha 4$  subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. *Nat Genet* 11:201–203
- Tareilus E, Roux M, Qin N, Olcese R, Zhou J, Stefani E, Birnbaumer L (1997) A *Xenopus* oocyte beta subunit: evidence for a role in the assembly/expression of voltage-gated calcium channels that is separate from its role as a regulatory subunit. *Proc Natl Acad Sci* 94:1703–1708
- Walker D, Bichet D, Campbell KP, De Waard M (1998) A  $\beta_4$  isoform-specific interaction site in the carboxyl-terminal region of the voltage-dependent  $\text{Ca}^{2+}$  channel  $\alpha_{1A}$  subunit. *J Biol Chem* 273:2361–2367
- Walker D, Bichet D, Geib S, Mori E, Cornet V, Snutch TP, Mori Y (1999) A new  $\beta$  subtype-specific interaction in  $\alpha_{1A}$  subunit controls P/Q-type  $\text{Ca}^{2+}$  channel activation. *J Biol Chem* 274:12383–12390
- Walker D, De Waard M (1998) Subunit interaction sites in voltage-dependent  $\text{Ca}^{2+}$  channels. *Trends Neurosci* 21:148–154
- Wallace RH, Wang DW, Singh R, Scheffer IE, George Al Jr, Phillips HA, Saar K, et al (1998) Febrile seizures and generalized epilepsy associated with a mutation in the  $\text{Na}^+$ -channel  $\beta 1$  subunit gene *SCN1B*. *Nat Genet* 19:366–370
- Wei X, Neely A, Lacerda AE, Olcese R, Stefani E, Perez-Reyes E, Birnbaumer L (1994) Modification of  $\text{Ca}^{2+}$  channel activity by deletions at the carboxyl terminus of the cardiac  $\alpha 1$  subunit. *J Biol Chem* 269:1635–1640
- Yamaguchi H, Hara M, Strobeck M, Fukasawa K, Schwartz A, Varadi G (1998) Multiple modulation pathways of calcium channel activity by a  $\beta$  subunit. *J Biol Chem* 273:19348–19356
- Zuberi SM, Eunson LH, Spauschus A, De Silva R, Tolmie J, Wood NW, McWilliam RC, et al (1999) A novel mutation in the human voltage-gated potassium channel gene (*Kv1.1*) associates with episodic ataxia type 1 and sometimes with partial epilepsy. *Brain* 122:817–825